acute-kidney-injury | Media Room

Press Release May 27, 2020

Kantum Pharma Highlights New Research Demonstrating Beneficial Effects of P2Y14 Antagonist in Acute Kidney Injury

Paper published by company's scientific founder in Journal of Clinical Investigation and findings highlighted in Nature Reviews Nephrology

Late-Breaking KIDNEY Clinical Trial Results: RenalGuard Therapy Prevents Acute Kidney Injury After Cardiac Surgery

Automated Diuresis Technology; Trial Results Presented at American Society of Nephrology 2019

Kantum Pharma Founder to Present Preclinical Data Demonstrating Beneficial Effects of P2Y14 Antagonist in Acute Kidney Injury at the American Society of Nephrology Annual Meeting

Preclinical results support the therapeutic potential of KB-1801 for the prevention of Cardiac Surgery-Associated Acute Kidney Injury and advancement into clinical development